Eli Lilly’s Jaypirca (pirtobrutinib) has succeeded in its fourth Phase III trial in chronic lymphocytic leukaemia (CLL). The ...
Eli Lilly and Company (NYSE: LLY) today announced positive topline results from the Phase 3 BRUIN CLL-322 trial of Jaypirca ...
The BRUIN CLL-322 trial evaluated the safety and efficacy of pirtobrutinib plus venetoclax and rituximab in previously treated CLL/SLL patients.
6don MSN
Eli Lilly's Jaypirca builds case with fourth positive phase 3 trial in blood cancer patients
Eli Lilly and Co. LLY shares were little changed in Monday’s premarket session. The U.S. drug giant shared results from the ...
Richter transformation with CNS involvement in CLL patients results in poor prognosis and limited survival, with a median overall survival of 13 months. Treatment strategies for RT-CNS are often ...
Commercial liso-cel produced ORR 85% and CR/CRi/CRu 56% in R/R CLL/SLL, exceeding liso-cel monotherapy outcomes in TRANSCEND CLL 004 and approximating the liso-cel+ibrutinib cohort. Pre–CAR-T exposure ...
"The magnitude of the progression-free survival benefit, early overall survival trend and safety profile observed in BRUIN CLL-313 offer highly compelling evidence for the potential role of ...
Explore 2026 CLL frontline choices, from all-oral acalabrutinib–venetoclax to MRD-guided care, plus pipeline advances and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results